Comparative study conducted in Taiwan showed that silodosin improve symptoms of lower urinary tract symptoms (lower urinary tract symptoms, LUTS) that accompany benign prostate enlargement (benign prostatic hyperplasia, BPH) as well as tamsulosin, and even more rarely cause side effects hypotension. As tamsulosin, silodosin is a class of drugs inhibiting alpha-1A-selective adrenoceptors, but higher selectivity. This was revealed by dr. Hong-Jeng Yu and colleagues from the National Taiwan University Hospital, Taipei, published online in the BJU International in mid-May 2011.
To find out whether a high-receptor selectivity in silodosin actually provide clinical benefit, the research team carry out a randomized double-blind study comparing tamsulosin silodosin in 209 patients with BPH. In the study for 12 weeks, patients were divided into two groups. Silodosin The first group received 4 mg twice daily, while the second group received tamsulosin 0.2 mg once daily (according to recommended doses in
